Sam Cooper

Co-Founder

Sam Cooper is deeply engrossed in groundbreaking research, harnessing advanced machine-learning tools to process high-dimensional phenotypic data. His overarching aim is to uncover and subsequently commercialize innovative drug targets that hold the potential to transform the medical landscape.

Notably, as a pivotal contributor at Phenomic, Sam has been instrumental in building one of the world's largest single-cell RNA datasets, meticulously concentrating on targeting solid tumors. Capitalizing on this exceptional resource, he's fervently engaged in the pursuit of highly selective targets situated within the tumor stroma. This intricate web of connective tissue is pivotal in cancer progression. At the forefront of Sam's efforts lies a lead target that was previously unexplored in the realm of drug development - a component of the extracellular matrix. With demonstrated efficacy in vivo, this target has the potential to be revolutionary for some of the most challenging cancer cases. Collaboratively, the objective is to dismantle cancer's formidable barriers.

Sam's academic journey is distinguished by his successful completion of a PhD under the aegis of the department of Computational Medicine at Imperial College. Supervised by Prof. Robert Glen and Dr. Chris Bakal from the Dynamical Cell Systems team at the Institute of Cancer Research, his research focus revolved around harnessing computational tools to unravel fundamental questions within the sphere of cancer biology. This confluence of expertise, research acumen, and unwavering dedication positions Sam as an invaluable asset within the realm of medical research and innovation.

Talks About
#python #softwaredevelopment #c

Preferred Locations
#NorthAmerica